Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients

American Journal of Hypertension

Volumn 29, Issue 4, 2016, Pages 528-536

  Hsu, Chien Yi ^a,b   Huang, Po Hsun ^a,b   Chen, Tz Heng ^a,b   Chiang, Chia Hung ^a   Leu, Hsin Bang ^a,b   Huang, Chin Chou ^a,b   Chen, Jaw Wen ^a,b   Lin, Shing Jong ^a,b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adipokine; Blood pressure; Chronic kidney disease; Endothelial dysfunction; Hypertension; Visfatin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC ACID DERIVATIVE; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; BIOLOGICAL MARKER; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRACHIAL ARTERY; CLINICAL EVALUATION; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; EVENT FREE SURVIVAL; FEMALE; FLOW MEDIATED DILATATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASODILATATION; BLOOD; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; COMPLICATION; KAPLAN MEIER METHOD; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TIME FACTOR; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CREATININE; CYTOKINES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84962535681     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpv132     Document Type: Article

References (38)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
2. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol 2013; 305:F1629-F1636.
3. Grubbs V, Lin F, Vittinghoff E, Shlipak MG, Peralta CA, Bansal N, Jacobs DR, Siscovick DS, Lewis CE, Bibbins-Domingo K. Body mass index and early kidney function decline in young adults: a longitudinal analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis 2014; 63:590-597.
4. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
5. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 1994; 14:1431-1437.
6. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32:3225-3234.
7. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009; 41:150-153.
8. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23:959-965.
9. Hsu CY, Huang PH, Chiang CH, Leu HB, Huang CC, Chen JW, Lin SJ. Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS One 2013; 8:e68644.
10. Huang PH, Chen YH, Chen YL, Wu TC, Chen JW, Lin SJ. Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart 2007; 93:1064-1070.
11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
12. Sabanayagam C, Wong TY, Tai ES. The CKD-EPI equation and MDRD study equation find similar prevalence of chronic kidney disease in Asian populations. Ann Intern Med 2009; 151:892-893.
13. Liao Y, Liao W, Liu J, Xu G, Zeng R. Assessment of the CKD-EPI equation to estimate glomerular filtration rate in adults from a Chinese CKD population. J Int Med Res 2011; 39:2273-2280.
14. Hsu TW, Kuo KL, Hung SC, Huang PH, Chen JW, Tarng DC. Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase- 2, -3, and -9. PLoS One 2013; 8:e70132.
15. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, Tsai HY, Lin FY, Chen JW, Lin SJ. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens 2010; 28:1655-1665.
16. Chiang CH, Huang PH, Chiu CC, Hsu CY, Leu HB, Huang CC, Chen JW, Lin SJ. Reduction of circulating endothelial progenitor cell level is associated with contrast-induced nephropathy in patients undergoing percutaneous coronary and peripheral interventions. PLoS One 2014; 9:e89942.
17. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950; 29:496-507.
18. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003; 14:S65-S70.
19. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 2012; 6:120-124.
20. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, Han JY, Han SY, Han KH, Kim HK, Cha DR. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295:F1485-F1494.
21. Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49:237-244.
22. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56:451-458.
23. Boini KM, Zhang C, Xia M, Han WQ, Brimson C, Poklis JL, Li PL. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010; 1801:1294-1304.
24. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damas JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Froland SS, Krohg-Sorensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115:972-980.
25. Huang Q, Guo Y, Zeng H, Xie W, Yan H, Ding H. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 2011; 36:93-100.
26. Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010; 15:225-229.
27. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, D'Angelo A, Cicero AF. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011; 34:145-151.
28. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, Fogari E, D'Angelo A, Cicero AF. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010; 33:790-795.
29. Kocelak P, Olszanecka-Glinianowicz M, Owczarek A, Bozentowicz- Wikarek M, Brzozowska A, Mossakowska M, Zdrojewski T, Grodzicki T, Wiçcek A, Chudek J. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy. J Am Soc Hypertens 2015; 9:1-8.
30. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78:356-365.
31. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178:1748-1758.
32. Romacho T, Villalobos LA, Cercas E, Carraro R, Sánchez-Ferrer CF, Peiró C. Visfatin as a novel mediator released by inflamed human endothelial cells. PLoS One 2013; 8:e78283.
33. Sun Y, Chen S, Song G, Ren L, Wei L, Liu N, Zhang D, Lv X. Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. Int J Mol Med 2012; 30:622-628.
34. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 2008; 31:758-760.
35. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8:12-28.
36. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 2008; 53:32-36.
37. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009; 23:241-248.
38. Villalobos LA, Uryga A, Romacho T, Leivas A, Sánchez-Ferrer CF, Erusalimsky JD, Peiró C. Visfatin/Nampt induces telomere damage and senescence in human endothelial cells. Int J Cardiol 2014; 175:573-575.